Duncan Kennedy
Plus aucun poste en cours
Fortune : 16 485 $ au 31/03/2024
Profil
Duncan Kennedy served as the Chief Financial Officer & Director at BTG Ltd.
from 2018 to 2019 and as the Chief Financial Officer & Executive Director at James Fisher & Sons Plc from 2021 to 2023.
Prior to these roles, he obtained an undergraduate degree from the University of Durham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 5 000 ( 0,01% ) | 16 485 $ | 31/03/2024 |
Anciens postes connus de Duncan Kennedy
| Sociétés | Poste | Fin |
|---|---|---|
| JAMES FISHER AND SONS PLC | Director of Finance/CFO | 01/12/2023 |
| BTG | Director of Finance/CFO | 31/12/2019 |
Formation de Duncan Kennedy
| University of Durham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JAMES FISHER AND SONS PLC | Transportation |
| Entreprise privées | 1 |
|---|---|
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
